Your browser doesn't support javascript.
loading
Peri-operative platelet-rich plasma in arthroscopic femoroacetabular impingement surgery: a randomized controlled trial.
Foo, Gen Lin; Knudsen, Joshua Sapong; Bacon, Catherine Jane; Mei-Dan, Omer; McConkey, Mark Owen; Brick, Matthew John.
Afiliação
  • Foo GL; Orthosports North Harbour Ltd., AUT Millenium, 17 Antares Place, Rosedale 0632, New Zealand.
  • Knudsen JS; New Zealand Orthopaedic Association, Level 12, Ranchhod Tower, 39, The Terrace, Wellington 6011, New Zealand.
  • Bacon CJ; Orthosports North Harbour Ltd. & School of Nursing, Faculty of Medical and Health Sciences, University of Auckland, New Zealand.
  • Mei-Dan O; Division of Sports Medicine and Hip Preservation, Department of Orthopaedics, University of Colorado School of Medicine, Boulder, Colorado, USA.
  • McConkey MO; Division of Arthroscopic, Reconstructive Surgery and Joint Preservation, Department of Orthopaedics, University of British Columbia, Vancouver, BC, Canada.
  • Brick MJ; Orthosports North Harbour Ltd., AUT Millenium , 17 Antares Place, Rosedale 0632, New Zealand.
J Hip Preserv Surg ; 8(1): 14-21, 2021 Jan.
Article em En | MEDLINE | ID: mdl-34567596
ABSTRACT
This study aimed to determine whether the addition of platelet-rich plasma (PRP) during hip arthroscopy improves functional outcomes in femoroacetabular impingement (FAI) surgery. This was a prospective randomized single-blinded trial of arthroscopic hip patients aged between 16 and 50 years with a diagnosis of FAI conducted at a single centre. Patients with any previous hip surgery and significant osteoarthritic changes (Tonnis grade > 2) were excluded. Before surgery, patients were randomly assigned to receive either a PRP injection or a saline placebo. Efficacy was evaluated at 6 months, 1 year and 2 years post-surgery using patient-reported outcomes. The short version International Hip Outcome Tool (iHOT12) was the primary outcome. Recruited patients (n = 113) were aged 36.0 ± 10.5 (mean ± standard deviation) years and 56% male. At baseline, iHOT12 scores of the PRP (mean 43.8 ± 22.4) and placebo groups (mean 45.2 ± 21.5) were similar. At a minimum follow-up of 2 years, both groups had improved iHOT12 scores (PRP mean 83.6 ± 13.4, control mean 77.1 ± 23.3), with no significant difference in change between the two groups (P = 0.19). There were no significant group differences for the change in Non-Arthritic Hip and Hip Disability and Osteoarthritis Outcome Score-Shortform scores between the two groups (P = 0.22 and 0.46, respectively). The present study does not support the peri-operative use of PRP in arthroscopic surgery for FAI for mid-term improvement. There were no significant differences in outcome between PRP and placebo groups at 2-year minimum follow-up after surgery.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2021 Tipo de documento: Article